---
title: "U.S. stock market update: Propanc Biopharma down 8.57%"
description: "Propanc Biopharma fell 8.57%; Allarity Therapeutics rose 132.13%, with a transaction volume of USD 493 million; Futu Holdings fell 0.72%, with a transaction volume of USD 140 million; Argenx rose 3.25"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254659213.md"
published_at: "2025-08-26T14:37:54.000Z"
---

# U.S. stock market update: Propanc Biopharma down 8.57%

> Propanc Biopharma fell 8.57%; Allarity Therapeutics rose 132.13%, with a transaction volume of USD 493 million; Futu Holdings fell 0.72%, with a transaction volume of USD 140 million; Argenx rose 3.25%, with a transaction volume of USD 111 million; AbbVie fell 0.14%, with a market capitalization of USD 366.1 billion

**U.S. Stock Market Midday Update**

Propanc Biopharma, down 8.57%, with increased trading volume. Based on recent key news:

1.  On August 25, Propanc Biopharma announced that its main asset "PRP" is about to enter Phase 1B clinical trials, raising market concerns about its funding needs and dilution risks, leading to an 8.57% drop in stock price.
    
2.  On August 25, there was increased market focus on financing and trial expansion for small biotech companies, with Propanc facing dilution risks that affected investor confidence.
    
3.  On August 25, Propanc provided a shareholder update that failed to alleviate market concerns about its financial situation, further exacerbating stock price volatility.
    

**Top Stocks by Industry Trading Volume**

Allarity Therapeutics rose 132.13%, with a trading volume of $493 million. Based on recent important news:

1.  On August 26, the U.S. FDA granted Allarity Therapeutics' ovarian cancer therapy Stenoparib Fast Track designation, driving the stock price up 42%.
    
2.  On August 26, Stenoparib obtained global development and commercialization rights, further boosting market confidence.
    
3.  On August 26, the FDA's Fast Track designation helps accelerate drug development and review, enhancing investor confidence.
    

Futai Pharmaceutical fell 0.72%, with increased trading volume. Based on recent important news:

1.  On August 25, Tianma Technology adjusted its seedling strategy to seize the opportunity of abundant Japanese eel seedlings, improving the company's profitability, which affected Futai Pharmaceutical's stock price, leading to a 0.72% decline.
    
2.  On August 24, the Chinese stock market was severely undervalued, suppressing investor enthusiasm for buying, leading to increased market volatility and a decline in Futai Pharmaceutical's stock price.
    
3.  On August 23, senior executives of Dameng Data were investigated, undermining market confidence and affecting Futai Pharmaceutical's stock price volatility.
    

Argenx rose 3.25%, with a trading volume of $111 million. Based on recent key news:

1.  On August 25, Argenx announced that Vyvgart achieved positive top-line results in the ADAPT SERON study and plans to submit an sBLA application to the FDA by the end of the year, resulting in a 3.25% increase in stock price.
    
2.  On August 25, RBC Capital set a target price of $850 for Argenx, further driving the stock price up.
    
3.  On August 25, Vyvgart Hytrulo pre-filled syringes were approved for self-injection, boosting market confidence.
    

**Top Stocks by Industry Market Capitalization**

AbbVie fell 0.14%, with increased trading volume. Based on recent important news:

1.  On August 25, AbbVie announced the acquisition of Gilgamesh's antidepressant bretisilocin for $1.2 billion, aiming to expand its psychiatric treatment drug pipeline, resulting in a slight decline of 0.14% in stock price
    
2.  On August 26, AbbVie reached an agreement with Gilgamesh to acquire its core candidate drug bretisilocin, and the market's reaction to the deal was relatively cautious.
    
3.  On August 26, analysts maintained their rating on AbbVie, with a target price between $231 and $255, and market sentiment remained stable

### Related Stocks

- [PPCB.US - Propanc Biopharma](https://longbridge.com/en/quote/PPCB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Propanc Biopharma 推进 PRP 候选药物进入胰腺癌的人体临床试验阶段 | Propanc Biopharma Inc. 正在推进其胰腺前酶制剂 PRP，计划于 2026 年开始进行针对胰腺癌的 I/II 期人类临床试验。尽管公司尚未发布临床研究结果，但它强调了 PRP 背后的科学依据，并承认在证明临床益处方面面临 | [Link](https://longbridge.com/en/news/272707596.md) |
| 市场监管总局约谈阿里巴巴、抖音、百度、腾讯、京东、美团、淘宝闪购等平台企业 | 市场监管总局于 2 月 13 日约谈了阿里巴巴、抖音、百度、腾讯、京东、美团和淘宝闪购等平台企业，要求它们遵守相关法律法规，落实主体责任，规范促销行为，并杜绝 “内卷式” 竞争，以维护公平竞争市场环境，促进平台经济的创新与健康发展。 | [Link](https://longbridge.com/en/news/275975190.md) |
| 群核科技拿下境外备案，“杭州六小龙” 首家上市公司渐近 |  | [Link](https://longbridge.com/en/news/275974694.md) |
| 中金公司重申对蔚来汽车 A 类股票（9866）的买入评级 | 中金公司分析师昨日对蔚来汽车（NIO Inc. Class A）维持了买入评级，并设定了 50.00 港元的目标价。情人节促销 - 70% 折扣解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策。通过最新的新闻和分析保持市 | [Link](https://longbridge.com/en/news/275967598.md) |
| Westfuller Advisors LLC 持有 NVIDIA 公司价值 596 万美元的股份 | Westfuller Advisors LLC 在第三季度将其在 NVIDIA Corporation (NASDAQ: NVDA) 的持股增加了 33.8%，目前持有 31,955 股，价值约 596 万美元。这使得 NVIDIA 占其投 | [Link](https://longbridge.com/en/news/275977152.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.